Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Donepezil for vascular cognitive impairment

Malouf, Reem, Birks, Jacqueline · 2004 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Vascular disease is the second commonest cause of dementia after Alzheimer's disease. There are difficulties in classifying patients with this type of cognitive impairment owing to varied clinical presentation and different types of arterial disease. There is some degree of overlap in the neuropathology of Alzheimer's and vascular dementia. Deficient cholinergic neurotransmission, a characteristic of Alzheimer's disease, has been postulated to contribute to the cognitive impairment of vascular disease of the brain. Cholinesterase inhibitors, such as donepezil, may therefore be a rational treatment. OBJECTIVES: To assess the clinical efficacy and tolerability of donepezil on cognitive function, clinical global impression, activities of daily living and social functioning of people with vascular cognitive impairment. SEARCH STRATEGY: Relevant randomized controlled trials were identified from a search of the Cochrane Dementia and Cognitive Improvement Group Specialized Register on 21 July 2003 using the terms donepezil, E2020 and Aricept. This Register consists of records from all major healthcare databases and many ongoing trials databases. Unpublished trials were requested from the drug company Eisai Inc and they provided us with the required data. SELECTION CRITERIA: All unconfounded randomized double-blind trials comparing donepezil with placebo were eligible for inclusion. Trials using combinations of donepezil with other pharmacological interventions were excluded. DATA COLLECTION AND ANALYSIS: Both reviewers assessed studies against the criteria for inclusion and extracted data. Data were pooled where appropriate, and weighted mean differences or Peto odds ratios with 95% confidence intervals calculated. Intention-to-treat analysis was undertaken when possible. MAIN RESULTS: Two large-scale, randomized, double-blind, parallel-group controlled trials were identified for inclusion. A total of 1219 people with mild to moderate cognitive decline due to probable or possible vascular dementia (according to the NINCDS/AIREN criteria and the Hachinski Ischemia Scale) were recruited. Donepezil, at doses of 5 or 10 mg a day was compared with placebo for 24 weeks. For each outcome measure, mean change from baseline at weeks 12 and 24, using a last observation carried forward analysis, was calculated. Cognitive function: The donepezil groups showed statistically significantly better performance than the placebo groups on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) at 12 and 24 weeks. The donepezil groups produced statistically significantly better scores than the placebo groups on the Mini-Mental State Examination (MMSE) at 12 and 24 weeks. Global function: The sum of the boxes of the Clinical Dementia Rating (CDR-SB) showed at 24 weeks a statistically significant benefit of 10 mg donepezil daily over both placebo and a 5 mg daily dosage. The Clinician's Interview-Based Impression of Change-plus version (CIBIC-plus) showed improved global function of participants taking 5 mg of donepezil daily compared with the placebo group but this was not seen in the higher dose group. Activities of daily living and social behaviour: On the Instrumental Activity of Daily Living (IADL) scale, there was no statistically significant difference between the groups taking donepezil 5mg per day donepezil and placebo, but the group taking 10 mg of donepezil a day showed benefit compared with placebo There were statistically significant benefit for donepezil at either dosage compared with placebo on the Alzheimer's Disease Functional Assessment and Change Scale (ADFACS). Tolerability and adverse effects: Broad range of adverse events were reported in the studies and data confirmed that donepezil was well tolerated, and most of the side effects were transient and were resolved by stopping the medication. Some of these events, especially nausea, diarrhoea, anorexia and cramp appeared more frequently on the 10 mg dose where there was a statistically significant difference compared with placebo. Drop-out: The drop-out rate was similar between the groups, 84.2% (330) patients completed the studies. The withdrawal rate was low and due mainly to side effects. REVIEWER'S CONCLUSIONS: Evidence from the available studies support the benefit of donepezil in improving cognition function, clinical global impression and activities of daily living in patients with probable or possible mild to moderate vascular cognitive impairment after 6 months treatment. Extending studies for longer periods would be desirable to establish the efficacy of donepezil in patients with advanced stages of cognitive impairment. Moreover, there is an urgent need for establishing specific clinical diagnostic criteria and rating scales for vascular cognitive impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004395.pub2

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 55

  1. Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1 · doi:10.1016/s0197-4580(04)81550-1
  2. Geldmacher, 2002, Donepezil slows functional deterioration in patients with vascular dementia, European Journal of Neurology, 9, 35
  3. Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6 · DOI
  4. Pratt RD Perdomo CA The Donepezil 307 VAD Study Group Donepezil improves cognition in patients with vascular dementia results from study 307 a 24 week randomized double blind placebo controlled trial Springfield Conference 2002 The International Symposium on Advances in Alzheimer Therapy, Geneva 2002 233
  5. Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials The 7th International Geneva Springfield Symposium on Advances in Alzheimer therapy 234
  6. Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x · DOI
  7. Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
  8. Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities., NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3 · doi:10.1016/s0197-4580(04)81551-3
  9. Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1 · doi:10.1016/s0197-4580(04)81550-1
  10. Farlow, 2003, Efficacy of donepezil in vascular dementia, Neurology, 61, 429
  11. Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6 · DOI
  12. Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials Springfield Conference 2002, The International Symposium on Advances in Alzheimer Therapy, Geneva 234
  13. Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x · DOI
  14. Salloway S Pratt RD Perdomo CA The Donepezil 308 Study Group Donepezil treated patients with vascular dementia demonstrated cognitive and global benefits: results from Study 308, a 24-week randomized double-blind, placebo-controlled trial The 8th International Conference on Alzheiner's Disease and Related Disoreders, July 20-25, Stockholm, Sweden 2002 Abstract No 219
  15. Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
  16. Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities, NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3 · doi:10.1016/s0197-4580(04)81551-3
  17. Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x · DOI
  18. Shua-Haim, 2000, Donepezil (Aricept R) treatment of multi infarct dementia the caregivers and clinical impression, American Journal of Alzheimer's Disease, 15, 201, 10.1177/153331750001500408 · DOI
  19. American Psychiatric Association, 1944, Diagnostic and Statistical Manual of Mental Disorders
  20. Berg, 1988, Clinical dementia rating (CDR), Psychopharmacology Bulletin, 24, 637
  21. Bowen, 1976, Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies 6-Davis P, Malony AJF. 1976. Selective loss of central cholinergic neurons in alzheimer's disease. Lancet 1403, Brain, 99, 459, 10.1093/brain/99.3.459 · DOI · Paper page
  22. Brust, 1988, Vascular dementia is overdiagnosed, Achives of Neurology, 45, 799
  23. Crow, 1973, An analysis of the learning defict following hyoscine administration to man, British Journal of Pharmacology, 49, 322, 10.1111/j.1476-5381.1973.tb08379.x · DOI
  24. Dawbarn, 2001, Neurobiology of Alzheimer's disease
  25. Desmond, 1993, Risk factors for cerebrovascualr disease as correlates of cognitive function in a stroke free cohort, Archives of Neurology, 50, 162, 10.1001/archneur.1993.00540020040015 · DOI · Paper page
  26. Ebly, 1995, Cognitive impairment in the non demented elderly result from the Canadian study of health and aging, Archiver of Neurology, 52, 612, 10.1001/archneur.1995.00540300086018 · DOI · Paper page
  27. Folstein, 1975, Mini-mental state a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  28. Gearing, 1995, The Consortium to establish a registry for Alzheimer's disease (CERAD) Part X neuropathology confirmation of the clinical diagnosis of Alzheimer's disease, Neurology, 45, 461, 10.1212/WNL.45.3.461 · DOI · Paper page
  29. Gottfries, 1994, The neurochemistry of vascular dementia, Dementia, 5, 163
  30. Graham, 1997, Prevalence and severity of cognitive impairment with and without dementia in an elderly population, Lancet, 349, 1793, 10.1016/S0140-6736(97)01007-6 · DOI · Paper page
  31. Hachinski, 1992, Preventable senility a call for action against the vascular dementias, Lancet, 340, 645, 10.1016/0140-6736(92)92177-H · DOI · Paper page
  32. Hebert, 1995, Epidemiology of vascular dementia, Neuroepidemiology, 14, 240, 10.1159/000109800 · DOI · Paper page
  33. Heyman, 1998, Cerebral infarction in patients with autopsy proven Alzheimer's disease CERAD part XVIII, Neurology, 51, 159, 10.1212/WNL.51.1.159 · DOI · Paper page
  34. Hofman, 1991, The prevalence of dementia in Europe a collaborative study of 1980-1990 findings Eurodem prevalence research group, International of Journal of Epidemiology, 20, 736, 10.1093/ije/20.3.736 · DOI · Paper page
  35. Jorm, 1991, Cross national comparisons of the occurrence of Alzheimer's disease and vascular dementias, European Archive of Psychaitry and Clinical neuroscience, 240, 218, 10.1007/BF02189530 · DOI
  36. Joynt, 1988, Vascular dementia too or too little, Archives of Neurology, 45, 801, 10.1001/archneur.1988.00520310119027 · doi:10.1001/archneur.1988.00520310119027
  37. Knopman, 1994, The clinician interview based impression (CIBI) a clinician's global change rating scale in Alzheimer's disease, Journal of Neurology, 44, 2315, 10.1212/WNL.44.12.2315 · DOI · Paper page
  38. Mann, The nucleus basalis of Meynert in multi infarct vascular dementia, Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi infarct vascular dementia, 71, 332
  39. Meyer, 1995, Procpective CT confirms differences between vascular and Alzheimer's dementia, Stroke, 269, 735, 10.1161/01.STR.26.5.735 · DOI
  40. Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x · DOI
  41. Mohs, 2001, A 1 year placebo controlled preservation of function survival study of donepezil in AD patients, Neurology, 57, 481, 10.1212/WNL.57.3.481 · DOI · Paper page
  42. Mulrow, 1997, Cochrane Collaboration Handbook
  43. O'Brien, 1994, How does cerebrovascular disease cause dementia, De Mentia, 5, 133
  44. O'Brien, 2001, Drugs for Alzheimer's disease, British Medical Journal, 323, 123, 10.1136/bmj.323.7305.123 · DOI
  45. Perry, 1977, Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activites in necropsy brain tissue, Journal of Neurological Science, 34, 247, 10.1016/0022-510X(77)90073-9 · DOI · Paper page
  46. Rockwood, 1997, Presence and treatment of vascular risk factors in patients with vascular cognitive impairment, Archives of Neurology, 54, 33, 10.1001/archneur.1997.00550130019010 · DOI
  47. Rockwood, 2000, Prevalence and outcomes of vascular cognitive impairment, Neurology, 54, 447, 10.1212/WNL.54.2.447 · DOI · Paper page
  48. Roman, 1993, Vascular dementia diagnostic criteria for research studies, Neurology, 43, 250, 10.1212/WNL.43.2.250 · DOI · Paper page
  49. Rosen, 1984, A new rating scale for Alzheimer's disease, American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
  50. Schwarz, 1999, Milameline (CI-979/RU35926) a muscarinic receptor agonist with cognition activating properties biochemical and in vivo characterization, Journal of Pharmacol Expermental Therapy, 291, 812, 10.1016/S0022-3565(24)35171-7 · DOI
  51. Toghi, 1996, Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as copared with Alzheimer's type dementia, Journal of Neural Transmission, 103, 1211, 10.1007/BF01271206 · DOI · Paper page
  52. Ueda, 1992, Prevalence and etiology of dementia in a Japanese community, Stroke, 23, 798, 10.1161/01.STR.23.6.798 · DOI · Paper page
  53. World Health Organization, 1992, International Statistic Classification of Disease and Related Health Problems, 25
  54. Zhang, 1990, The prevalence of dementia and Alzheimer's disease in Shanghai China impact of age gender and education, Annals of Neurology, 27, 428, 10.1002/ana.410270412 · DOI · Paper page
  55. Zhang, 1998, Mechanism of nicotine induced relaxation in the porcine basilar artery, Journal of Pharmacology Expermental Therapy, 284, 790, 10.1016/S0022-3565(24)37261-1 · DOI

Cited by

See all 170

Metadata

Authors
Malouf, R., & Birks, J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2004-01-26
Volume
2010
Issue
1
Pages
CD004395-CD004395
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1726357000
Cited by
170
References
9
FWCI
8.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Donepezil for vascular cognitive impairment. https://app.cochat.ai/papers/10.1002/14651858.cd004395.pub2
The paper
Malouf, R., & Birks, J. (2004). Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004395.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.